- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- CRD-4730, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Pasadena, California • Bloomfield Hills, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 86
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 74 more
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Vericiguat, Placebo
- Drug
- Lead sponsor
- Josef Stehlik
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
- Interventions
- Ketone Monoester (KE)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Heart Failure, Cardiomyopathy, Dilated
- Interventions
- AccuCinch® Ventricular Restoration
- Device
- Lead sponsor
- Ancora Heart, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 18
- States / cities
- San Francisco, California • Atlanta, Georgia • Louisville, Kentucky + 14 more
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Danicamtiv, Midazolam
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Fort Lauderdale, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
- Conditions
- Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
- Interventions
- SRD-001, Placebo
- Biological · Drug
- Lead sponsor
- Sardocor Corp.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- San Diego, California • San Francisco, California • St Louis, Missouri + 2 more
- Conditions
- Heart Failure NYHA Class III
- Interventions
- BaroStim
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Riverhead, New York
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- Antioxidant, Tetrahydrobiopterin (BH4), Exercise training
- Dietary Supplement · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- PRIME, COMBO
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Heart Failure
- Interventions
- REGN5381, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Torrance, California • Miami, Florida + 1 more
- Conditions
- Type2diabetes, Heart Failure With Reduced Ejection Fraction
- Interventions
- Empagliflozin 25 MG Oral Tablet, Placebo, Acipimox 250 Mg Oral Capsule
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Heart Failure, Decompensated Heart Failure, Heart Failure With Reduced Ejection Fraction
- Interventions
- Colchicine 0.6 mg, Control/Placebo group
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Heart Failure
- Interventions
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Device
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic
- Interventions
- VITARIA System
- Device
- Lead sponsor
- LivaNova
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 19 more
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 18
- States / cities
- Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
- Conditions
- Acute Heart Failure With Reduced Ejection Fraction
- Interventions
- APD418, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Peoria, Illinois • Houston, Texas + 2 more
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction
- Interventions
- Baroreflex Activation Therapy
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 2 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 51
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
- Interventions
- Liothyronine, Placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Vericiguat (Verquvo, BAY1021189)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Interventions
- JK07
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tulsa, Oklahoma
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
- Interventions
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
- Device
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Melbourne, Florida
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
- Interventions
- Ferric Carboxymaltose, Ferrous Sulfate
- Drug
- Lead sponsor
- Syed Hamza Mufarrih
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bowling Green, Kentucky